Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Orthopedics · Mucopolysaccharidosis type I

Do MPS I Treatments Cure Bone & Eye Problems?

At a Glance

Treatments like HSCT and ERT deliver missing enzymes through the bloodstream, but they cannot easily reach areas with poor blood supply, like bones and corneas. As a result, patients with MPS I may still experience ongoing bone growth issues and corneal clouding requiring specialized care.

While Hematopoietic Stem Cell Transplantation (HSCT) and Enzyme Replacement Therapy (ERT) are life-saving and critical treatments for Mucopolysaccharidosis type I (MPS I), they do not completely cure the disease, particularly when it comes to the bones and the eyes. These treatments work by delivering the missing enzyme to the body through the bloodstream. However, certain areas of the body, like the bones and the corneas, are notoriously difficult for these treatments to reach, meaning you or your child may still experience ongoing problems in these areas.

The Challenge of “Sanctuary Sites”

To understand why HSCT and ERT cannot fix every symptom, it is helpful to understand how these therapies work. Both treatments rely on the bloodstream to deliver the essential missing enzyme to the body’s cells. Tissues that have a rich blood supply—like the liver, spleen, and heart muscle—respond very well to treatment.

However, medical experts refer to the bones and the clear front part of the eyes (the corneas) as “sanctuary sites” [1][2]. These are avascular areas, meaning they lack a robust blood supply [2]. The cornea naturally has no blood vessels at all, and the growth plates of bones consist of dense cartilage that is very difficult for enzymes to penetrate [1]. Because the circulating enzymes cannot easily get inside these tissues, the buildup of complex sugars called glycosaminoglycans (GAGs) continues in these specific areas, leading to persistent symptoms despite an otherwise successful transplant or ongoing ERT [3][4].

What This Means for Bone Health

Even with a successful stem cell transplant, bone abnormalities (medically called dysostosis multiplex) often persist and can progress over time [4][1]. The cartilage at the ends of growing bones continues to struggle with GAG buildup, which alters how the bones develop and grow [1].

As you or your child grows, you will need to continue monitoring skeletal health closely. Many individuals with MPS I eventually require targeted orthopedic surgeries [4]. Common issues that may need surgical intervention later in life include:

  • Hip problems: Conditions like hip dysplasia (where the hip socket doesn’t fully cover the ball of the thighbone) or hip displacement are very common and often require reconstructive surgery [4][5].
  • Spinal issues: Curvature of the spine (kyphosis) or spinal cord compression can develop and may necessitate bracing or surgery [1].
  • Joint stiffness: Ongoing joint restrictions might require physical therapy and sometimes surgical release [1].
  • Carpal tunnel syndrome: Nerve compression in the wrists is frequent and may require a minor surgery to relieve pressure [6].

What This Means for Vision

The cornea is a classic sanctuary site. For this reason, corneal clouding—a signature feature of MPS I—has a minimal response to systemic treatments like ERT or HSCT [7]. While these treatments can sometimes stabilize the clouding or slow its progression, they rarely reverse existing cloudiness [1][7].

Ongoing care from an ophthalmologist (a specialist in eye diseases) is necessary. If the corneal clouding progresses to a point where it significantly impairs vision, a corneal transplant (penetrating keratoplasty) may be recommended [8]. It is important to know that even after a corneal transplant, clouding can sometimes recur years later, though a successful transplant can provide long-lasting visual improvement [8]. Other eye complications, such as increased pressure in the eye (glaucoma) or retinal changes, also need regular monitoring [9].

Moving Forward: Your Care Team

It is completely normal to hope that a stem cell transplant or starting ERT will be a 100% cure. Celebrating the immense, life-saving benefits of these treatments is important. While HSCT can allow enzyme-producing cells to reach the brain to protect cognitive function, standard intravenous ERT cannot cross the blood-brain barrier [10]. However, both treatments are absolutely vital for protecting the heart, liver, and other major organs [11].

Managing expectations for the bones and eyes will help you plan for future care. Maintaining a strong, multidisciplinary medical team that includes a pediatric or adult orthopedic surgeon and an ophthalmologist is essential to ensuring the best possible quality of life [12].

Common questions in this guide

Why do bone and eye problems continue after MPS I treatment?
Bones and the front of the eyes (corneas) lack a strong blood supply, making them 'sanctuary sites.' This means treatments given through the bloodstream, like ERT and stem cell transplants, cannot easily reach them to deliver the missing enzyme.
Will a stem cell transplant cure corneal clouding in MPS I?
No, a stem cell transplant or enzyme replacement therapy rarely reverses existing corneal clouding because the cornea has no blood vessels to deliver the treatment. Ongoing monitoring by an ophthalmologist is necessary, and a corneal transplant may eventually be needed.
What bone surgeries might be needed after MPS I treatment?
Even with successful systemic treatment, individuals with MPS I may still need targeted orthopedic surgeries as they grow. Common procedures address hip dysplasia, spinal curvature, joint stiffness, and carpal tunnel syndrome.
Can ERT treat cognitive symptoms in MPS I?
Standard intravenous Enzyme Replacement Therapy (ERT) cannot cross the blood-brain barrier. However, a successful stem cell transplant can allow enzyme-producing cells to reach the brain to help protect cognitive function.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How often should we schedule X-rays or spinal MRIs to monitor for hip and spine changes?
  2. 2.What specific signs or symptoms should prompt us to schedule an early appointment with the orthopedic surgeon?
  3. 3.Does the current level of corneal clouding affect vision, and at what point would we consider a corneal transplant?
  4. 4.What physical therapy or joint-safe exercises do you recommend to help maintain mobility and manage stiffness?
  5. 5.What early warning signs of spinal cord compression or carpal tunnel syndrome should I watch for at home?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (12)
  1. 1

    Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement.

    Hampe CS, Wesley J, Lund TC, et al.

    Biomolecules 2021; (11(2)) doi:10.3390/biom11020189.

    PMID: 33572941
  2. 2

    Laronidase-loaded liposomes reach the brain and other hard-to-treat organs after noninvasive nasal administration.

    Schuh RS, Franceschi EP, Brum BB, et al.

    International journal of pharmaceutics 2024; (660()):124355 doi:10.1016/j.ijpharm.2024.124355.

    PMID: 38897489
  3. 3

    MPS I: Early diagnosis, bone disease and treatment, where are we now?

    Kingma SDK, Jonckheere AI

    Journal of inherited metabolic disease 2021; (44(6)):1289-1310 doi:10.1002/jimd.12431.

    PMID: 34480380
  4. 4

    Progression of Hip Dysplasia in Mucopolysaccharidosis Type I Hurler After Successful Hematopoietic Stem Cell Transplantation.

    Langereis EJ, den Os MM, Breen C, et al.

    The Journal of bone and joint surgery. American volume 2016; (98(5)):386-95 doi:10.2106/JBJS.O.00601.

    PMID: 26935461
  5. 5

    Total hip arthroplasty in Hurler syndrome - 8 years follow up - A case report with review of literature.

    Gautam D, Malhotra R

    Journal of orthopaedics 2018; (15(1)):111-113 doi:10.1016/j.jor.2018.01.036.

    PMID: 29657451
  6. 6

    Carpal tunnel syndrome in mucopolysaccharidosis I: a registry-based cohort study.

    Viskochil D, Muenzer J, Guffon N, et al.

    Developmental medicine and child neurology 2017; (59(12)):1269-1275 doi:10.1111/dmcn.13545.

    PMID: 28892147
  7. 7

    Ophthalmological Findings in Mucopolysaccharidoses.

    Tomatsu S, Pitz S, Hampel U

    Journal of clinical medicine 2019; (8(9)) doi:10.3390/jcm8091467.

    PMID: 31540112
  8. 8

    Ocular Manifestations of Hurler-Scheie Syndrome: Recurrence of Host Disease in the Corneal Transplant.

    Kölkedi Z, Csutak A, Szalai E

    Molecular syndromology 2023; (14(1)):44-50 doi:10.1159/000525453.

    PMID: 36777710
  9. 9

    Bilateral Foveal Cysts in Mucopolysaccharidosis Type I (Hurler Syndrome): Response to Acetazolamide With Insights From Multimodal Retinal Imaging and Electrophysiology.

    Lobo R, Al-Hinai A, Al Busaidi A

    Case reports in ophthalmological medicine 2025; (2025()):5349202 doi:10.1155/crop/5349202.

    PMID: 41312338
  10. 10

    Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease.

    Hsu YH, Liu RS, Lin WL, et al.

    Orphanet journal of rare diseases 2017; (12(1)):109 doi:10.1186/s13023-017-0649-6.

    PMID: 28595620
  11. 11

    Mucopolysaccharidosis Type I Newborn Screening: Best Practices for Diagnosis and Management.

    Clarke LA, Atherton AM, Burton BK, et al.

    The Journal of pediatrics 2017; (182()):363-370 doi:10.1016/j.jpeds.2016.11.036.

    PMID: 27939258
  12. 12

    Challenges in Diagnosing and Managing Hurler Syndrome: A Case Report.

    Achiatar LS, Hazoor HB, Adwani R, et al.

    Cureus 2024; (16(8)):e67056 doi:10.7759/cureus.67056.

    PMID: 39286678

This page is for informational purposes only and does not replace professional medical advice. Always consult your orthopedic surgeon, ophthalmologist, or genetic specialist about your or your child's specific MPS I care plan.

Get notified when new evidence is published on Mucopolysaccharidosis type 1.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.